Last Updated : October 30, 2024
Details
FilesGeneric Name:
everolimus
Project Status:
Complete
Therapeutic Area:
Renal angiomyolipoma associated with tuberous sclerosis
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0814-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Renal angiomyolipoma associated with TSC.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | July 12, 2023 |
|---|---|
| Call for patient/clinician input closed | September 01, 2023 |
| Call for industry input open | July 13, 2023 |
| Call for industry input closed | September 01, 2023 |
| Submission received | July 06, 2023 |
| Clarification: - Patient input submission received from TSC Canada | |
| Review initiated | July 18, 2023 |
| Expert committee meeting (initial) | February 01, 2024 |
| Draft recommendation posted for stakeholder feedback | February 15, 2024 |
| End of feedback period | March 01, 2024 |
| Final recommendation posted | May 16, 2024 |
| Canada's Drug Agency review report(s) posted | January 22, 2024 |
Files
Last Updated : October 30, 2024